SubHero Banner

Belviq XR® (lorcaserin) – New formulation approval

July 19, 2016 – Eisai announced the FDA approval of Belviq XR (lorcaserin) extended-release oral tablets, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

Download PDF